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ABSTRACT 1 
 2 
Objective:  Preclinical data suggest an important role for the sarcoma proto-oncogene tyrosine 3 
kinase (SRC) in the oncogenesis of epithelial ovarian cancer (EOC) or primary peritoneal 4 
carcinoma (PPC).  The Gynecologic Oncology Group (GOG) conducted a Phase II trial to 5 
evaluate the efficacy and safety of dasatinib, an oral SRC-family inhibitor in EOC/PPC and 6 
explored biomarkers for possible association with clinical outcome. 7 
Methods:  Eligible women had measurable, recurrent or persistent EOC/PPC and had received 8 
one or two prior regimens which must have contained a platinum and a taxane.  Patients were 9 
treated with 100 mg orally daily of dasatinib continuously until progression of disease or adverse 10 
effects prevented further treatment.  Primary endpoints were progression-free survival (PFS) ≥6 11 
months and response rate.  Serial plasma samples were assayed for multiple biomarkers.  12 
Circulating free DNA was quantified as were circulating tumor and endothelial cells.   13 
Results:  Thirty-five (35) patients were enrolled in a two-stage sequential design.  Of the 34 14 
eligible and evaluable patients, 20.6% (90% confidence interval: 10.1%, 35.2%) had a PFS ≥6 15 
months; there were no objective responses.  Grade 3-4 toxicities were gastrointestinal (mostly 16 
nausea and emesis; n=4), pulmonary (dyspnea and/or pleural effusion; n=4) and pain (n=5), 17 
and infrequent instances of anemia, malaise, insomnia, rash, and central nervous system 18 
hemorrhage.  Lack of clinical activity limited any correlation of biomarkers with outcome. 19 
Conclusion:  Dasatinib has minimal activity as a single-agent in patients with recurrent 20 
EOC/PPC. 21 
 5 
INTRODUCTION 22 
Despite initially high remission rates, at least 75% of women diagnosed with advanced 23 
stage epithelial ovarian carcinoma (EOC) will relapse and ultimately die of their disease [1].  24 
Treatment of these patients once they develop recurrent disease remains a major problem.  The 25 
need for new therapeutic strategies is evident.  The SRC family of kinases (SFK) is a nine 26 
member group of membrane associated non-receptor tyrosine kinases that are involved in a 27 
variety of cellular signaling pathways [2].  The SFK is involved in the oncogenesis of numerous 28 
tumors including ovarian cancer.  SRC regulates many intracellular signaling pathways 29 
responsible for various important tumor cell functions such as proliferation, motility and invasion, 30 
angiogenesis, and survival.  SRC has been found to be overexpressed in a majority of late 31 
stage ovarian tumors and cell lines [3]. 32 
SRC is a component of signaling pathways downstream of many growth factor 33 
receptors, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor 34 
receptor (VEGFR), and MNNG transforming gene product (c-MET) [4].  Increased resistance to 35 
traditional chemotherapy is modulated by SRC through increased activity of RAS and AKT [5]. 36 
Inhibition of SRC enhanced the activity of cytotoxic agents, including cisplatin, gemcitabine, and 37 
paclitaxel through the activation of caspase-3 in pre-clinical models [5-7].  In addition, tumor 38 
growth was blunted when human ovarian cancer cells carrying an antisense SRC construct 39 
were implanted into mice bearing these xenografts [8]. 40 
VEGF is an important growth factor for ovarian cancer cells [9].  VEGF was significantly 41 
down-regulated by SRC inhibition and microvessel density was reduced [10].  Anti-VEGF 42 
therapy has demonstrated activity in patients with recurrent and primary disease [11,12].  VEGF 43 
stimulation of its receptor increased tyrosine phosphorylation of focal adhesion kinase, p130 44 
CAS and paxillin [13].  Increased activity of these mediators leads to an increased epithelial-to-45 
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mesenchymal transition (EMT), a crucial step to enhancing the metastatic potential of these 46 
cancer cells [14].  SRC is a key intermediate in the EMT process [15,16].  In addition, caveolin-1 47 
expression indirectly promotes cell-cell adhesion in ovarian cancer cells [17,18].  SRC interferes 48 
with caveolin function also promoting EMT and encouraging tumor spread. 49 
Dasatinib is a potent oral inhibitor of breakpoint cluster region-Abelson fusion protein 50 
(BCR-ABL), c-KIT, ephrin type-A receptor 2 (EPHA2), c-FMS, and SFK [19,20].  These kinases 51 
are implicated in oncogenic process and maintaining the metastatic phenotype of many 52 
cancers.  Dasatinib’s mechasnism of action depends on itsuccessfully competing for the ATP 53 
binding site contained in the kinase domain.  The agent is widely approved for chronic 54 
myelogenous leukemia and Ph+ acute lymphoblastic leukemia and is now under investigation 55 
for treating various solid tumors [21]. 56 
Based on these observations, the evaluation of dasatinib in patients with recurrent EOC 57 
was undertaken by the Gynecologic Oncology Group (GOG).  Translational research objectives 58 
were included to explore the association between biomarkers and patient outcome.  Biomarkers 59 
included cell-free DNA (cfDNA), circulating tumor cells (CTCs), circulating endothelial cells 60 
(CECs), circulating endothelial precursors (CEPs), and seven plasma biomarkers relevant to 61 
dasatinib treatment (EGF and its soluble receptor [sEGFR], VEGF and its soluble receptors 62 
[sVEGFR1, sVEGFR2, sVEGFR3], and insulin like growth factor binding protein 2 [IGFBP2]). 63 
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PATIENTS AND METHODS 64 
Eligibility 65 
Eligible patients had a histologically-confirmed diagnosis of EOC or primary peritoneal 66 
carcinoma, measurable disease as defined by Response Evaluation Criteria in Solid Tumors 67 
(RECIST) [22], a GOG performance status of 0-2, and adequate bone marrow (absolute 68 
neutrophil count ≥1,500/µL, platelet count ≥100,000/µL), renal (serum creatinine ≤1.5 x the 69 
upper limit of normal), and hepatic function (total bilirubin ≤1.5 x the upper limit of normal, and 70 
transaminases and alkaline phosphatase ≤2.5 x the upper limit of normal).  No biomarker based 71 
method was used for patient selection.  Eligible patients were permitted to have up to two prior 72 
cytotoxic regimens, but if a patient had only one prior regimen, she was required to have a 73 
platinum-free interval of less than 12 months or to have progressed during or have persistent 74 
disease after platinum-based therapy.  Prior biological agents were permitted other than those 75 
known to inhibit SRC.  Patients with prior radiation to more than 25% of marrow bearing areas, 76 
therapeutic warfarin treatment, or signs and/or symptoms of bowel obstruction were excluded. 77 
Patients provided written informed consent consistent with federal, state, and local institutional 78 
review board at each participating GOG institution in accordance with assurances filed with and 79 
approved by the Department of Health and Human Services. 80 
Treatment Plan and Dose Modifications 81 
Dasatinib (Bristol-Myers Squibb, New York, NY) was administered orally at an initial 82 
dose of 100 mg once daily until disease progression or adverse effects required interruption, 83 
reduction or discontinuation of therapy.  Dose level –1 was 70 mg daily and dose level +1 was 84 
70 mg twice daily.  Although dosing was continuous, a cycle was defined as 28 days.  Dasatinib 85 
was supplied by Bristol-Myers Squibb, Inc. 86 
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Toxicity was graded using the National Cancer Institute Common Toxicity Criteria 87 
version 3.0 (NCI-CTCAE v3.0).  For first occurrence of febrile neutropenia and/or documented 88 
grade 4 neutropenia, dasatinib was held until the absolute neutrophil count (ANC) was grade ≤2 89 
then reduced by one dose level.  Patients with grade 4 thrombocytopenia had their drug held 90 
until grade ≤1 and then were reduced by one dose level.  The next cycle of dasatinib did not 91 
begin until the ANC was ≥1,500/µl and the platelet count was ≥100,000/µl.  Therapy was 92 
allowed to be delayed up to a maximum of two weeks.  Patients who failed to recover adequate 93 
counts within this time were removed from study.  Prophylactic use of myeloid growth factors 94 
was prohibited.  Patients who experienced grade ≥2 non-hematologic toxicity had therapy held 95 
until resolution to grade 0-1 up to a maximum of 14 days.  Dasatinib was then restarted at 70 96 
mg daily.  If toxicity recurred to grade 2 or worse, the patient would discontinue study drug. 97 
Exceptions to the above modifications included:  liver function tests were required to be grade 3 98 
or worse toxicity before dose modification was required.  There was no dose adjustment for 99 
fatigue or alopecia.  Doses were reduced for gastrointestinal toxicities only if they could not be 100 
controlled with medical management.  Fluid retention (pleural effusion and/or ascites) was 101 
managed with early initiation of diuretic treatment (furosemide and/or spironolactone.  Cavity 102 
drainage was performed as clinically indicated.  Once a patient’s dose was reduced, no 103 
subsequent increases were permitted. 104 
Patients with no grade ≥1 toxicities after cycle 1 were escalated one dose level (70 mg 105 
twice daily) beginning with cycle 2 of treatment.  This dose escalation was included based on 106 
early data that solid tumors may require higher doses of dasatinib to achieve clinical activity 107 
compared with the doses used to treat patients with CML [23,24]. 108 
Response Assessment 109 
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Patients were evaluated clinically every four weeks and radiographically every eight 110 
weeks.  The same evaluation modality was used throughout for each patient on study.  111 
Response criteria used were as defined by RECIST [22]. 112 
 113 
Translational Research 114 
Plasma and whole blood specimens were collected for translational research prior to cycles 1, 2 115 
and 3.  Detailed methodology and references for isolating and phenotyping CTC and CEC/CEP 116 
can be found in the supplemental material [online only].  Methods for determining circulating 117 
levels of serum biomarkers and extraction and quantification of total plasma cell-free DNA 118 
(cfDNA) are also summarized in the supplemental online material. 119 
Statistical Methods 120 
We anticipated that the effect of dasatinib might be either cytotoxic or cytostatic. 121 
Therefore, the primary endpoint of this study included both objective tumor response and the 122 
proportion of patients alive and progression-free after six months PFS-6).  Time on study was 123 
assessed from date of registration and included all eligible treated patients.  124 
The null hypothesis, i.e. an “uninteresting” level of efficacy, was determined from 125 
analysis of an historical GOG dataset, based on a similar patient population from clinical trials of 126 
study drugs now considered inactive or minimally active.  The null hypothesis jointly specified 127 
the probability of a patient experiencing a tumor response to be ≤10% and the probability of a 128 
patient being alive and free from PFS-6 to be ≤15%.  For the purpose of study design, a 20% 129 
increase (to 25% for tumor response or to 35% for PFS-6) were considered clinically significant. 130 
The two-stage, bivariate, flexible method of Sill and Yothers [25] was used with a goal of limiting 131 
patient exposure to inactive agents while restricting the probabilities of type I and type II errors 132 
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to about 10%.  If the regimen were to demonstrate sufficient activity in the first stage (with 35 133 
patients, this required >5 objective tumor responses or >8 patients with PFS-6), then the study 134 
would target a total of 53 patients (cumulatively) in stage 2.  Signed-rank tests were used to test 135 
changes from baseline in biomarkers, and Wilcoxon rank sum tests were used to compare 136 
changes or ratios for patients who had PFS for at least 6 months versus those who did not. 137 
Proportional hazards models were used to compare PFS by high (≥ median) versus low 138 
(<median) baseline (pre-cycle 1) levels of each parameter; both unadjusted models and models 139 
adjusted for age and performance status were examined. 140 
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RESULTS 141 
Patients and Eligibility 142 
Thirty-five patients were enrolled.  One patient was deemed ineligible because 143 
inadequate data were available.  Patient characteristics are listed in Table 1.  A majority of 144 
patients (58.8%) received two prior regimens.  All patients had a performance status of 0 or 1. 145 
Treatment and Response 146 
            Patients received a median of two cycles (range, 1-12) of protocol therapy.  Of the 23 147 
patients who received two or more cycles, 15 were escalated to 140 mg of dasatinib daily (70 148 
mg bid) and two were reduced to 70 mg daily.  149 
There were no responders.  Also, only seven patients (20.6%; 90% confidence interval: 150 
10.1%, 35.2%) were PFS-6 (Table 2).  Therefore, the protocol criteria for continuing to the 151 
second stage of accrual were not met.  Of the seven patients with PFS ≥6 months, five had two 152 
prior treatment regimens while two had received one prior regimen, and all had platinum-153 
resistant disease (<6 months platinum-free interval) Median PFS was 2.1 months (first and third 154 
quartiles: 1.8 and 4.9 months).  Median overall survival (OS) was 17.7 months (first quartile: 155 
10.8 months, third quartile has not been reached; Figure 1). 156 
Toxicity 157 
The most commonly observed grade 3 toxicities were gastrointestinal (mostly nausea 158 
and emesis), pulmonary (dyspnea and/or pleural effusion), and pain (Table 3).  There were 159 
single cases of grade 3 or 4 anemia, malaise, insomnia, rash, and central nervous system 160 
hemorrhage.  161 
 162 
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Translational research 163 
Dasatinib related biomarkers 164 
Bead-based immunoassays were used to measure circulating levels of seven dasatinib 165 
related biomarkers in plasma collected pre-cycles 1 (n=27), 2 (n=23), and 3 (n=15).  Fifteen 166 
patients submitted samples at all three time points.  Median biomarker levels (ng/mL) are 167 
presented (Supplemental Table S1).  There was a significant increase in the levels of 168 
sVEGFR2, sVGEFR3, and IGFBP2 between baseline and pre-cycle three in these patients.  169 
There was no association between baseline levels of plasma biomarkers and outcome (PFS 170 
and OS) nor between changes in biomarker levels and six-month PFS outcome (data not 171 
shown). 172 
Circulating cfDNA 173 
Total cfDNA from plasma collected pre-cycles 1 (n=28), 2 (n=23), and 3 (n=15) was 174 
quantified using a real-time PCR TaqMan Assay and primers directed to β-actin, β-globin, and 175 
GAPDH.  Median cfDNA totals (GE/mL) are presented (Supplemental Table S2).  cfDNA 176 
increased from baseline to pre-cycle 2 and decreased between pre-cycle 2 and pre-cycle 3; 177 
these changes were not significant.  There were no statistically significant associations between 178 
baseline measures of cfDNA and outcome (PFS and OS) nor between changes in biomarker 179 
levels and six-month PFS outcome (data not shown). 180 
Circulating Tumor and Endothelial Cells 181 
Whole blood was collected pre-cycles 1 (n=26), 2 (n=21), and 3 (n=12) for CTC and 182 
CEC enumeration; CEC VEGFR expression was examined.  Twenty-six patients were 183 
evaluated for at least one time point; nine patients submitted samples at all three time points. 184 
Median biomarker values are presented (Supplemental Table 3).  Sixteen patients had >1 CTC 185 
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at one of the three timepoints, with nine patients having >1 at baseline.  All patients had CECs 186 
(range 14-800) at each timepoint tested.  There were no statistically significant associations 187 
between baseline CTCs or CECs and outcome (PFS and OS) nor between changes in 188 
biomarker levels and six-month PFS outcome (data not shown). 189 
CEC VEGFR expression was used to examine whether dasatinib had an effect on 190 
endothelial cell activation and whether activation correlates with outcome.  We anticipated the 191 
percent of VEGFR+ CEC to decrease with a positive anti-angiogenic treatment effect.  There 192 
was no significant association between baseline CEC VEGFR expression and outcome (PFS 193 
and OS) nor between changes in biomarker levels and six-month PFS outcome (data not  194 
shown).  195 
 196 
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DISCUSSION 197 
Dasatinib was well tolerated but had minimal activity in patients with recurrent ovarian or 198 
primary peritoneal carcinoma.  With SRC reported to be overexpressed in approximately 90% of 199 
ovarian cancers [3], no prescreening was performed to determine eligibility. 200 
SRC occupies a strategic position in many cell signaling pathways affecting cell 201 
proliferation, growth, and survival [4].  It has an important role in mediating the epithelial-to-202 
mesenchymal transition enhancing the metastatic potential of ovarian cancer cells [15,16].  203 
Activated SRC is required for VEGF expression, which has already been shown to be important 204 
in ovarian cancer biology and as an important therapeutic target.  SRC expression was 205 
associated with a drug resistant phenotype and SRC inhibition by transfecting SRC antisense 206 
oligonucleotides (or by small molecule inhibitors) reversed drug resistance in preclinical models 207 
[6].  Gene expression profiles of ovarian cancer tumors were able to identify with greater than 208 
80% accuracy which tumors were likely to be resistant to primary platinum-based therapy 209 
[26,27].  These profiles identified expression signatures consistent with activation of SRC which 210 
in the future may be used to direct therapeutic strategies. 211 
SRC protein expression usually correlated with the degree of SRC pathway 212 
deregulation.  The more deregulated the pathway, the higher the activated protein expression.  213 
Platinum-resistant ovarian cancers have been shown to be more likely to have deregulation of 214 
the SRC pathway [5,26].  Kaplan-Meier survival analysis showed that SRC pathway 215 
deregulation is associated with a poor survival.  Konecny and colleagues tested a panel of 34 216 
ovarian cancer cell lines and reported that 71% were highly sensitive to dasatinib [28].  Teoh et 217 
al, evaluated the in vitro activity of dasatinib alone and in combination with paclitaxel and 218 
carboplatin in ovarian cancer cell lines [29].  Dasatinib demonstrated anti-proliferative activity 219 
alone and synergistic activity with the cytotoxic in the cell lines with either SRC pathway 220 
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deregulation and/or high SRC protein expression.  Dasatinib did not decrease SRC protein 221 
expression, but completely abrogated the activation of SRC in all cell lines tested.  These data 222 
suggest dasatinib may help prime cells for apoptosis induced by cytotoxic chemotherapy.  223 
Investigators at Duke University have conducted a phase I trial of carboplatin, paclitaxel, and 224 
dasatinib [NCT00672295], but have yet to report these results. 225 
It is not surprising that there was little single agent activity of dasatinib in this trial in light 226 
of what has been learned about SRC since the conception and conduct of this trial.  Preclinical 227 
data support evaluating SRC inhibition in cancers with a predilection for developing metastases 228 
to bone based on SRC’s suppression of osteoclast function.  A phase II trial of single agent 229 
dasatinib investigated its activity in chemotherapy-naïve men with castrate resistant prostate 230 
cancer (CRPC).  A 43% stable disease rate (SDR) at 12 weeks and a 19 % SDR was 231 
observed.(30)  This level of activity was very similar to the results of current trial in patients with 232 
recurrent ovarian cancer.  A biochemical marker of drug activitywas identified with a decline in 233 
N-telopeptide, a marker if bone resorption predictive of adverse skeletal events, in men with 234 
CRPC treated with dasatinib.  Dasatinib has been similarly studied in patients with triple 235 
negative breast cancer, Her 2 positive/hormone receptor positive breast cancer with response 236 
rates of 4-5%.  No or minimal activity also was observed in phase II trials of monotherapy 237 
dasatinib in patients with head and neck cancer, glioma and small cell lung cancer (21,31).  238 
None of these trials pre-selected patients based on any predictive biomarkers of dasatinib 239 
activity. While SRC may be effective (under some circumstances) in suppressing tumor growth, 240 
it is not able as monotherapy to cause regression of established tumors.  There are 241 
compensatory pathways that can bypass blockade of SRC.  For example, SRC silencing results 242 
in significant increase in FGR levels (another  member of the SFK) [32].  Alternatively, activation 243 
of JAK may re-establish downstream STAT signaling after inhibition of SFKs [33]. 244 
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The low activity of dasatinib as a single agent should not preclude evaluation as part of 245 
combination regimens, either concomitantly or in sequence prior to chemotherapy if it is borne 246 
out that dasatinib can serve a priming function in ovarian cancers with a high degree of SRC 247 
pathway deregulation.  In this regard, Pathak and Godwin have recently completed in vitro high-248 
throughput screening (HTS) using a siRNA library targeting signaling molecules related to 249 
receptor tyrosine kinases in combination with dasatinib.  Such screening would identify second-250 
site molecules that can be targeted in combination with SRC inhibition to synergistically improve 251 
dasatinib efficacy in patients and to identify a potential gene signature predictive of response to 252 
dasatinib therapy (personal communication).  The clinical significance of these genes identified 253 
through the HTS as being capable of synergizing with SRC inhibition is now being evaluated in 254 
blinded tumor biopsy samples from the patients that participated in this trial.  255 
Our correlative studies did not show any significance between the biomarkers tested and 256 
patient outcome, mainly due to no clinical response on this study.  There was a significant 257 
increase in the levels of sVEGFR2, sVEGFR3, and IGFBP2 between baseline and pre-cycle 3 258 
in the 15 patients submitting samples at all three time points similar to the data reported by 259 
Strauss and colleagues [34].  There were no statistically significant changes in the three 260 
housekeeping genes from baseline in these patients.  The mechanisms of the occurrence of 261 
cfDNA in blood under normal and pathological conditions are not yet fully understood.  cfDNA 262 
might be influenced by apoptosis, necrosis, decreased DNAase activity in circulating cancer 263 
cells, as well as clearance by liver/kidney, and modification status of cfDNA.  In this study, 16 264 
patients had ≥1 CTC at one of the three time points; 9 had ≥1 at baseline.  Further investigation 265 
of the relationship between cfDNA and circulating CTCs and the predictive value of changes in 266 
CTC in patients with ovarian cancer is needed..  267 
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FIGURE LEGEND 
 
Figure 1:  Kaplan-Meier plots for overall and progression-free survival. 
 
